Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Rifaximin for Preventing Acute Graft Versus Host Disease: Impact On Plasma Markers of Inflammation and T Cell Activation.

Muna Qayed, MD, Amelia Langston, MD, Kuang-Yueh Chiang, MD, PhD, Joseph Hilinski, MD, Conrad Cole, MD, MSc, Stephanie McMillan, RN, Pamela Rowland, RN, MS, CPNP, Andre Rogatko, PhD, John Horan, MD, MPH

Blood (2009) 114 (22): 4664.

https://doi.org/10.1182/blood.V114.22.4664.4664

Published: 2009

Journal Articles

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

Amelia A Langston, MD, Sujatha Murali, MD, Stephanie McMillan, RN, Leonard T. Heffner, MD, Sagar Lonial, MD, Edmund K. Waller, MD, PhD, Christopher R. Flowers, MD, Jonathan Kaufman, MD, Morgan L. McLemore, MD, Rajni Sinha, MD, Mary J Lechowicz, MD, H. Jean Khoury, MD, Elliott F. Winton, MD

Blood (2008) 112 (11): 3644.

https://doi.org/10.1182/blood.V112.11.3644.3644

Published: 2008

Journal Articles

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Sagar Lonial, MD, Jonathan Kaufman, MD, Amelia A. Langston, MD, Leonard T. Heffner, MD, Claire Torre, Mary J. Lechowicz, MD, Christopher Flowers, MD, Stephanie McMillan, RN, Michael Arnold, Ned K. Waller, MD, PhD

Blood (2007) 110 (11): 949.

https://doi.org/10.1182/blood.V110.11.949.949

Published: 2007

Journal Articles

Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.

Sujatha Murali, MD, Elliott F. Winton, MD, Stephanie McMillan, RN, Sagar Lonial, MD, Ned Waller, MD, Leonard Heffner, MD, Christopher Flowers, MD, Jonathan L. Kaufman, MD, Mary Jo Lechowicz, MD, H. Jean Khoury, MD, Amelia Langston, MD

Blood (2006) 108 (11): 1960.

https://doi.org/10.1182/blood.V108.11.1960.1960

Published: 2006

Journal Articles

A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.

Amelia A. Langston, MD, Stephanie McMillan, RN, Sagar Lonial, MD, Kenneth Smith, MD, Edmund K. Waller, MD, PhD, Leonard T. Heffner, MD, Silvana Bucur, MD, Istvan Redei, MD, Christopher Flowers, MD, Mary J. Lechowicz, MD, Elliot Winton, MD

Blood (2004) 104 (11): 1814.

https://doi.org/10.1182/blood.V104.11.1814.1814

Published: 2004

NARROW

Rifaximin for Preventing Acute Graft Versus Host Disease: Impact On Plasma Markers of Inflammation and T Cell Activation.

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.

A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.

Email alerts

ASH Publications

American Society of Hematology

Rifaximin for Preventing Acute Graft Versus Host Disease: Impact On Plasma Markers of Inflammation and T Cell Activation.

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.

A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only